Sandra Calvin, SVP, Chief Accounting Officer at Travere Therapeutics, Inc. (TVTX), sold 1,097 shares at $21.90 ($24K) on 2023-01-24, disclosed to the SEC on 2023-01-26.
Scheduled sale ($24k) by SVP, Chief Accounting Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $21.90 | 905 | $20K | 82.7% |
| 2 | $21.63 | 192 | $4K | 17.3% |
| Total | $21.85 avg | 1,097 | $24K | 100% |
| Filing → |
| TVTX | SELL | 2026-02-03 | $139K | — | Filing → |
| TVTX | SELL | 2025-12-29 | $296K | — | Filing → |
| TVTX | SELL | 2025-12-16 | $105K | — | Filing → |